Print Email

Practice Resources  |  Skin Toxicities Study Group

EGFR Inhibitor Skin Toxicity Tool (MESTT)
©MASCC, Multinational Association for Supportive Care in Cancer™ •  All rights reserved worldwide. 

icon  About the MESTT

The MESTT© was developed by the MASCC Skin Toxicity Study Group in 2008 as a tool to assist oncology health professions with the monitoring and reporting of dermatologic AEs in EGFRI-treated patients. The MESTT is an event-specific grading system that can be used to standardize assessment, optimize the use of EGFR inhibitors and enable researchers to conduct more informative, controlled studies in this patient population.
This project was supported by: OSI Pharmaceuticals and Amgen, Inc.
*Dr. Mario E. Lacouture (Organizing and Overall Meeting Chair) is supported by a Zell Scholarship from the Robert H Lurie Comprehensive Cancer Center.

download  Download the Guidelines and Skin Toxicity Tools

alt View the MESTT  (1.1MB ppt)
alt Caring for your skin, hair and nails on "Targeted Therapies" alt - Download this brochure for patients suffering with EGFRI side effects.
alt EGFR Inhibitor–Related Dermatologic Toxicities: Applying MASCC Guidelines in Prevention and Treatment
      Upon completion of this activity, participants should be able to:

  • Administer effective prophylactic treatment strategies for dermatologic toxicities associated with EGFR inhibitors in oncology patients receiving therapy with these agents.
  • Employ optimal management strategies for long-term treatment-related adverse events associated with EGFR inhibitors
  • Identify and treat dermatologic infections associated with EGFR inhibitor therapy in oncology patients receiving treatment with these agents.
  • Counsel patients on the anticipated dermatologic toxicities associated with EGFR inhibitors and optimal prophylactic and management strategies.

alt Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities alt - Supportive Care in Cancer, Volume 19, Number 8, 1079-1095, DOI: 10.1007/s00520-011-1197-6.  Mario E. Lacouture, Milan J. Anadkat, René-Jean Bensadoun, Jane Bryce, Alexandre Chan, Joel B. Epstein, Beth Eaby-Sandy, Barbara A. Murphy and MASCC Skin Toxicity Study Group

MESTT© Approval
Non-profit entities may use the MESTT free of charge. Commercial companies require written approval and we request a nominal fee. The agreement is described in a letter/contract with the given commercial company. Please contact the MASCC Executive Director at mascc.office@mascc.org for approval procedure or questions.

Translations  -  Translation Policy 
There are no translations at this time. If you would like to translate these materials, please contact Donald Gubitosa at dgubitosa@mascc.org

MASCC Skin Toxicity Participants

Robert Baran, MD
Andrei Barasch, DMD
Ethan Basch, MD
Alice Chen, MD
Janet E. Dancey, MD
Beth Eaby, CRNP
Lawrence Einhorn, MD
Joel B. Epstein, DMD
Lindy P Fox, MD
Judi Johnson, RN, PhD
Mark Kris, MD
Sandra Kurtin, RN
Mario E Lacouture*, MD
Michael L. Maitland, MD
Bernardo L. Rapoport, MD
Cynthia Rittenberg, RN
Elise Olsen, MD
Siegfred Segaert, MD
Andy Trotti, MD
Lynne Wagner, PhD
Dennis P West, MD


MESTT ©MASCC, Multinational Association for Supportive Care in Cancer™ •  All rights reserved worldwide.
For Questions or additional information, contact the Executive Director at mascc.office@mascc.org.